drug_type
RELEVANT_DRUG
intervention_type
Viral vector therapeutic vaccine
drug_description
Replicating arenavirus-based therapeutic cancer vaccine (Pichinde virus vector) encoding non-oncogenic HPV16 antigens to elicit tumor-specific cytotoxic T-cell responses.
nci_thesaurus_concept_id
C173149
nci_thesaurus_preferred_term
HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202
nci_thesaurus_definition
A cancer vaccine consisting of replication-attenuated arenavirus encoding the inactivated fusion protein of the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) serotype 16, with potential immunomodulating and antineoplastic activities. Upon administration, HPV 16 E6/E7-encoding arenavirus vaccine HB-202 induces expression of the E6/E7 proteins and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.
drug_category
GENE THERAPY
drug_class
Vaccine
drug_delivery_route
Intravenous
drug_mechanism_of_action
Replication-attenuated arenavirus (Pichinde virus) vector encoding non-oncogenic HPV16 E6/E7 antigens transduces host cells/antigen-presenting cells, driving intracellular expression and presentation of HPV16 antigens to activate and expand HPV16-specific cytotoxic CD8+ T cells, which recognize and kill HPV16-expressing tumor cells.
drug_name
HB-202
nct_id_drug_ref
NCT06513884